Segment Information

6 Months Ended

Jun. 30, 2016

Segment Information

Segment Information

Note 7. Segment Information

The Company operates in one business segment, which primarily focuses on the development and global commercialization of genomic based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. As of June 30, 2016, the majority of the Company’s product revenues have been derived from sales of one product, the Oncotype DX breast cancer test.

The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2016		2015		2016		2015
	(In thousands)				(In thousands)
United States	$	69,644	$	60,692	$	140,139	$	118,409
Outside of the United States		12,330		9,927		22,729		20,362
Total revenues	$	81,974	$	70,619	$	162,868	$	138,771